top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Experienced Cardio Sales & Other Professions Coming Available from Amarin Layoffs


Category: Employee recruiting

Opportunity: US and European sales reps are coming available from AMRN layoffs

Company: Amarin Corporation

Product/Asset: VASCEPA/VAZKEPA

Issue: Work force (including sales force) layoff

Latest trigger event for Opp: PR July 18, 2023

Target Companies: Job recruiters and cardio companies


Details:

Amarin Corporation is focused on discovering, developing and delivering new therapeutics and treatments to cardiovascular disease patients. VASCEPA was approved in the U.S in 2020 and VAZKEPA was approved in the EU 2021 both for cardiovascular disease. On July 18, 2023, Amarin announced that they will be restructuring their organization. With that, Amerin will be reducing all U.S. sales force positions and non-sales position by about 30%. This opens the opportunity for companies to recruit these sales representatives and other experienced cardio professionals.



About Amarin Corporation

Company Type: Public Company

Market Cap (7/21/23): $109,000,000

Location: Dublin, Ireland & Bridgewater, New Jersey

Cash (Q1 2023): $304,400,000

Burn rate/quarter: $-22,060,000

Technology Focus: Cardiovascular disease

Latest stage asset: Approved

Indications: Cardiovascular diseases

Key employees: Subscribe to learn more!


 

💡 Do you sell your products or services to biopharma companies? 💡



BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.



Article History:

Originally posted 8/9/23 (RB)



bottom of page